Eli Lilly & Co (LLY) Price & Analysis

Compare

18,829 Followers

LLY Stock Chart & Stats

Day’s Range― - ―

52-Week Range$623.78 - $943.00

Previous CloseN/A

Volume1.27M

Average Volume (3M)5.81M

Market Cap

$695.83B

Enterprise Value$737.86B

Total Cash (Recent Filing)$3.55B

Total Debt (Recent Filing)$39.90B

Price to Earnings (P/E)48.8

Beta0.70

Next Earnings

Oct 30, 2025

EPS Estimate

6.36

Last Dividend Ex-Date

Aug 15, 2025

Dividend Yield0.78%

Share Statistics

EPS (TTM)6.31

Shares Outstanding946,456,800

10 Day Avg. Volume3,701,076

30 Day Avg. Volume5,806,343

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.06

Enterprise Value/Revenue13.85

Enterprise Value/Gross Profit16.77

Enterprise Value/Ebitda37.53

Forecast

1Y Price Target

$904.76

Price Target Upside21.79% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering21

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessVerzenio achieved an overall survival benefit in the Ph3 monarchE trial in HR+, HER2-, high-risk early breast cancer.

Drug EfficacyOrforglipron, an oral GLP-1, has shown promising weight loss efficacy in phase 3 studies and could benefit from the FDA's national priority voucher program.

Market StrategyThe direct-to-consumer sales model combined with a fee-based subscription for orforglipron unlocks significant revenue potential, especially for long-term users.

Bears Say

Market CompetitionWeight loss was encouragingly on the higher end of the expected 8-10% range, and notably outperforming Novo’s semaglutide STEP-2 trial in a similar population.

Side EffectsMore patients – 10.6% of those on the highest dose – stopped taking the pill due to side effects compared with existing injections.

Eli Lilly & Co News

Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!

Investors will find loads of stock market stories worth reading about on Friday in the TipRanks daily wrap-up. ...

12h ago

AMD

DAL

Eli Lilly’s (LLY) Lung Cancer Drug Given ‘Breakthrough Therapy’ Designation

The pharma giant is a major player in cancer medications. ...

13h ago

LLY

Bank of America Stays Bearish on Hims & Hers Stock (HIMS) Due to ‘Competitive Pressures’

Bank of America remains bearish on telehealth firm Hims & Hers ($HIMS) due to “competitive pressures in the...

20h ago

LLY

HIMS

HIMS Stock Climbs 7% after Eli Lilly’s Knockoff Case Falls Flat

The stock of Hims & Hers Health Inc. ($HIMS) climbed nearly 7% on Wednesday after a court ruling...

1d ago

LLY

NVO

Eli Lilly receives breakthrough therapy designation for olomorasib

Eli Lilly (LLY) announced that the FDA has granted Breakthrough Therapy designation to olomorasib, in combination with anti-PD-1...

2d ago

LLY

PFE, MRK, LLY: Florida Become First U.S. State to End Vaccine Mandates, Including for Schools

There are many conspiracies related to vaccines. ...

2d ago

LLY

MRK

BMO Capital Markets Reaffirms ‘Buy Rating’ on Eli Lilly Stock (LLY)

The company’s sales are expected to takeoff with its new weight-loss pill. ...

3d ago

BMO

LLY

Mixed options sentiment in Eli Lilly with shares up 0.15%

Mixed options sentiment in Eli Lilly (LLY), with shares up $1.13, or 0.15%, near $736.32. Options volume relatively...

3d ago

LLY

Analyst Forecasts $25 Billion of Annual Sales for Eli Lilly’s (LLY) New Weight-Loss Pill

Management plans to seek approval for the new drug by year’s end. ...

3d ago

LLY

NVO

Moderately bullish activity in Eli Lilly with shares up 0.31%

Moderately bullish activity in Eli Lilly (LLY), with shares up $2.25, or 0.31%, near $734.83. Options volume relatively...

3d ago

LLY

Eli Lilly’s relaxin study stopped early over low probability of benefit

According to a report from Nature Medicine over the weekend, a study of Eli Lilly’s (LLY) relaxin, a...

3d ago

LLY

Tectonic pullback on Eli Lilly relaxin data ‘overdone,’ says Truist

Truist analyst Danielle Brill notes that shares of Tectonic Therapeutic (TECX) are off by greater than 30% following...

3d ago

LLY

TECX

Chinese companies supplying ingredients for weight loss drugs, Reuters reports

Some Chinese companies looking to make generic versions of Novo Nordisk’s (NVO) Wegovy also supplied ingredients for more...

4d ago

LLY

NVO

Novo says Wegovy cut risk of heart attack, death by 57% compared to tirzepatide

Novo Nordisk (NVO) presented data from the STEER real-world study of evidence gathered from actual patient experiences at...

4d ago

LLY

NVO

LLY FAQ

What was Eli Lilly & Co’s price range in the past 12 months?

Eli Lilly & Co lowest stock price was $623.78 and its highest was $943.00 in the past 12 months.

What is Eli Lilly & Co’s market cap?

Eli Lilly & Co’s market cap is $695.83B.

When is Eli Lilly & Co’s upcoming earnings report date?

Eli Lilly & Co’s upcoming earnings report date is Oct 30, 2025 which is in 54 days.

How were Eli Lilly & Co’s earnings last quarter?

Eli Lilly & Co released its earnings results on Aug 07, 2025. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.599 by $0.711.

Is Eli Lilly & Co overvalued?

According to Wall Street analysts Eli Lilly & Co’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Eli Lilly & Co pay dividends?

Eli Lilly & Co pays a Quarterly dividend of $1.5 which represents an annual dividend yield of 0.78%. See more information on Eli Lilly & Co dividends here

What is Eli Lilly & Co’s EPS estimate?

Eli Lilly & Co’s EPS estimate is 6.36.

How many shares outstanding does Eli Lilly & Co have?

Eli Lilly & Co has 946,456,800 shares outstanding.

What happened to Eli Lilly & Co’s price movement after its last earnings report?

Eli Lilly & Co reported an EPS of $6.31 in its last earnings report, beating expectations of $5.599. Following the earnings report the stock price went down -14.135%.

Which hedge fund is a major shareholder of Eli Lilly & Co?

Currently, no hedge funds are holding shares in LLY

Eli Lilly & Co Stock Smart Score

Neutral

Fundamentals

Return on Equity

86.70%

Trailing 12-Months

Asset Growth

40.41%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Eli Lilly & Co

Eli Lilly and Company (LLY) is a global healthcare leader based in Indianapolis, Indiana, that focuses on the research, development, manufacturing, and marketing of pharmaceutical products. The company operates in several sectors, including diabetes care, oncology, immunology, neuroscience, and pain management. Eli Lilly's core products include insulin therapies, cancer treatments, and medications for various chronic and acute conditions, including depression and autoimmune disorders.

Eli Lilly & Co (LLY) Earnings & Revenues

Historic Earnings Reports

LLY Company Deck

LLY Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call presented a strong financial performance with significant revenue growth and positive clinical trial results, despite challenges such as pricing declines and CVS exclusion impacting the growth rate.View all LLY earnings summaries

LLY Revenue Breakdown

67.44% U.S.

15.36% Europe

9.48% ROW

4.03% Japan

3.69% China

LLY Stock 12 Month Forecast

Average Price Target

$904.76

▲(21.79% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"699":"$699","822":"$822","945":"$945","1068":"$1,068","1191":"$1,191"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1190,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.19K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":904.76,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$904.76</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":700,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$700.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[699,822,945,1068,1191],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,735.19,770.1753846153847,805.1607692307692,840.1461538461539,875.1315384615385,910.1169230769231,945.1023076923077,980.0876923076924,1015.073076923077,1050.0584615384614,1085.043846153846,1120.0292307692307,1155.0146153846154,{"y":1190,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,735.19,748.2338461538462,761.2776923076924,774.3215384615385,787.3653846153846,800.4092307692308,813.453076923077,826.496923076923,839.5407692307692,852.5846153846154,865.6284615384616,878.6723076923076,891.7161538461538,{"y":904.76,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,735.19,732.483076923077,729.7761538461539,727.0692307692308,724.3623076923077,721.6553846153846,718.9484615384615,716.2415384615385,713.5346153846154,710.8276923076924,708.1207692307693,705.4138461538462,702.7069230769231,{"y":700,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":952.73,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 67,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":877.77,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 73,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":812.71,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":795.04,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":767.41,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":806.26,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 68,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":916.73,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":801.82,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":790.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 64,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":745.48,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 75,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":774.2,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 76,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":760.66,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 80,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":735.19,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >